Author Correction: A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD

Katherine E Irwin^{1

2}, Pei Jasin¹, Kerstin E Braunstein¹, Irika R Sinha^{1

2}, Mark A Garret³, Kyra D Bowden^{1

2}, Koping Chang^{1

4}, Juan C Troncoso^{1

5}, Abhay Moghekar⁵, Esther S Oh^{1

6

7}, Denitza Raitcheva⁸, Dan Bartlett⁸, Timothy Miller⁹, James D Berry³, Bryan J Traynor^{5

10

11

12}, Jonathan P Ling¹, Philip C Wong^{13

14}

Affiliations

¹ Department of Pathology, Johns Hopkins Medicine, Baltimore, MD, USA.
² Department of Neuroscience, Johns Hopkins Medicine, Baltimore, MD, USA.
³ Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, Boston, MA, USA.
⁴ Department and Graduate Institute of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
⁵ Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA.
⁶ Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
⁷ Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine, Baltimore, MD, USA.
⁸ Biogen, Cambridge, MA, USA.
⁹ Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
¹⁰ Neuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
¹¹ National Institute of Neurological Disorders, National Institutes of Health, Bethesda, MD, USA.
¹² RNA Therapeutics Laboratory, Therapeutics Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
¹³ Department of Pathology, Johns Hopkins Medicine, Baltimore, MD, USA. wong@jhmi.edu.
¹⁴ Department of Neuroscience, Johns Hopkins Medicine, Baltimore, MD, USA. wong@jhmi.edu.

Published Erratum

Katherine E Irwin et al. Nat Med. 2024 May.

. 2024 May;30(5):1504.

doi: 10.1038/s41591-024-02966-z.

¹ Department of Pathology, Johns Hopkins Medicine, Baltimore, MD, USA.
² Department of Neuroscience, Johns Hopkins Medicine, Baltimore, MD, USA.
³ Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, Boston, MA, USA.
⁴ Department and Graduate Institute of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
⁵ Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA.
⁶ Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.
⁷ Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine, Baltimore, MD, USA.
⁸ Biogen, Cambridge, MA, USA.
⁹ Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
¹⁰ Neuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
¹¹ National Institute of Neurological Disorders, National Institutes of Health, Bethesda, MD, USA.
¹² RNA Therapeutics Laboratory, Therapeutics Development Branch, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
¹³ Department of Pathology, Johns Hopkins Medicine, Baltimore, MD, USA. wong@jhmi.edu.
¹⁴ Department of Neuroscience, Johns Hopkins Medicine, Baltimore, MD, USA. wong@jhmi.edu.

No abstract available

Erratum for

A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD.
Irwin KE, Jasin P, Braunstein KE, Sinha IR, Garret MA, Bowden KD, Chang K, Troncoso JC, Moghekar A, Oh ES, Raitcheva D, Bartlett D, Miller T, Berry JD, Traynor BJ, Ling JP, Wong PC. Irwin KE, et al. Nat Med. 2024 Feb;30(2):382-393. doi: 10.1038/s41591-023-02788-5. Epub 2024 Jan 26. Nat Med. 2024. PMID: 38278991 Free PMC article.